Trump Secures Lower Prices for Obesity Medications
Washington D.C., Thursday, 6 November 2025.
The Trump administration finalizes agreements with Eli Lilly and Novo Nordisk to reduce obesity drug prices to $149 per month, enhancing Medicare access and potentially transforming public health outcomes.
Background of the Pricing Agreement
In a strategic move aimed at reducing healthcare costs and improving public health, the Trump administration has successfully negotiated agreements with Eli Lilly and Novo Nordisk to lower the prices of their obesity medications, including Wegovy and Zepbound, to $149 per month. This initiative is aligned with the administration’s broader ‘most favored nation’ drug pricing strategy, which seeks to ensure that U.S. consumers pay prices comparable to those in other nations [1][2][3].
Implications for Medicare and Public Health
The agreements mark a significant shift in Medicare coverage for weight loss drugs, which have traditionally been expensive and thus inaccessible to many patients. Currently, the list prices for these medications exceed $1,000 per month, creating a substantial financial barrier for many beneficiaries [2][3]. By lowering the cost to $149, the administration aims to enhance accessibility and affordability, potentially transforming the landscape of obesity management in the U.S. [4].
Expected Outcomes and Long-Term Benefits
The expected outcomes of these agreements are profound. By widening access to effective weight management medications, the administration anticipates a reduction in obesity-related health issues such as diabetes and cardiovascular diseases, ultimately decreasing overall healthcare expenditures [2][5]. Moreover, this initiative could set a precedent for future negotiations, encouraging pharmaceutical companies to consider more competitive pricing strategies [1][3].
Challenges and Next Steps
Despite these promising developments, several challenges remain. The specifics of Medicare coverage eligibility are yet to be clarified, and the reach of these agreements across different patient demographics is still uncertain [2][3]. As negotiations continue, stakeholders are keenly watching for official announcements and further details on implementation. The administration’s ability to maintain momentum on this issue will be crucial in realizing the full benefits of the agreements [4].